Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
To investigate the clinical efficacy of budesonide enteric-coated capsules (trade name: Naifukang) in patients with subclassication of focal segmental glomerulosclerosis of immunoglobulin A nephropathy (IgAN), and to analyze the impacts of baseline renal function, pathological features, and comorbid metabolic diseases on therapeutic outcomes, so as to provide evidence for individualized treatment.
A retrospective analysis was performed on the clinical data of 22 IgAN patients with subclassication of focal segmental glomerulosclerosis who received Naifukang treatment from October 2024 to September 2025. Data collected included demographic characteristics, baseline comorbidities, pathological parameters, Naifukang administration regimens, and key laboratory indicators before and after treatment, such as 24-hour urinary protein excretion (24h UPE), serum creatinine (Scr), and estimated glomerular filtration rate (eGFR). Descriptive analysis and intergroup comparison were employed to assess differences in therapeutic efficacy.
Among the 22 patients, 14 were male (63.6%), and middle-aged patients (31-45 years) accounted for 68.2%. The proportions of patients with hypertension, hyperlipidemia, and hyperuricemia were 59.1%, 63.6%, and 59.1%, respectively. After treatment, 63.6% of patients achieved a ≥30% reduction in 24h UPE compared with baseline, and 68.2% of patients had an eGFR fluctuation of <5 ml/min/1.73m². The proteinuria improvement rate in the group with baseline eGFR ≥40 ml/min/1.73m² (78.9%) was significantly higher than that in the group with eGFR <40 ml/min/1.73m² (33.3%) (P<0.05). Following comprehensive management, there was no significant difference in therapeutic efficacy between patients with 3 comorbid metabolic diseases and those without (P>0.05).(Tab. 1, Fig. 1)
Tab. 1 Treatment effect
Group
n
≥30% reduction in 24h UPE (n, %)
eGFR fluctuation of <5 ml/min (n, %)
P Value
Overall Efficacy
All Patients
22
14 (63.6%)
15 (68.2%)
-
By Baseline Renal Function
Baseline eGFR ≥ 40
19
15 (78.9%)
14 (73.7%)
P=0.027
Baseline eGFR < 40
3
1 (33.3%)
By Metabolic Disease
Combined with Metabolic Diseases)
13
8 (61.5%)
10 (76.9%)
P＞0.05
Combined without Metabolic Disease)
9
6 (66.7%)
Budesonide enteric-coated capsules exhibit definite overall efficacy in the treatment of IgAN with subclassication of focal segmental glomerulosclerosis, and patients with better baseline renal function gain more significant benefits. High-risk patients with renal insufficiency require combined intensive therapy, and synchronous control of metabolic parameters can ensure therapeutic efficacy in patients with comorbid metabolic diseases.
